Silvercrest Asset Management Group LLC Decreases Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

Silvercrest Asset Management Group LLC lowered its position in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 5.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 358,386 shares of the medical instruments supplier's stock after selling 22,217 shares during the quarter. Silvercrest Asset Management Group LLC owned approximately 1.46% of ICU Medical worth $55,611,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Point72 Asset Management L.P. lifted its position in ICU Medical by 63.2% during the fourth quarter. Point72 Asset Management L.P. now owns 245,340 shares of the medical instruments supplier's stock worth $38,069,000 after buying an additional 95,030 shares in the last quarter. ProShare Advisors LLC lifted its position in ICU Medical by 45.9% during the fourth quarter. ProShare Advisors LLC now owns 6,613 shares of the medical instruments supplier's stock worth $1,026,000 after buying an additional 2,081 shares in the last quarter. Quantedge Capital Pte Ltd purchased a new position in ICU Medical during the fourth quarter worth approximately $2,529,000. Occudo Quantitative Strategies LP purchased a new position in ICU Medical during the fourth quarter worth approximately $911,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in ICU Medical by 4.1% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,204 shares of the medical instruments supplier's stock worth $1,894,000 after buying an additional 478 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company's stock.

Wall Street Analyst Weigh In

ICUI has been the topic of a number of analyst reports. KeyCorp reduced their price objective on ICU Medical from $209.00 to $191.00 and set an "overweight" rating on the stock in a research report on Monday, April 21st. Raymond James cut their target price on ICU Medical from $197.00 to $187.00 and set a "strong-buy" rating for the company in a research note on Friday, May 9th. Needham & Company LLC reissued a "hold" rating on shares of ICU Medical in a research note on Tuesday, April 8th. Finally, StockNews.com raised ICU Medical from a "hold" rating to a "buy" rating in a research note on Sunday. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $192.67.

Insider Activity at ICU Medical

In related news, COO Christian B. Voigtlander sold 5,555 shares of ICU Medical stock in a transaction on Monday, May 19th. The stock was sold at an average price of $138.00, for a total value of $766,590.00. Following the completion of the transaction, the chief operating officer now directly owns 2,389 shares in the company, valued at approximately $329,682. This trade represents a 69.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director David C. Greenberg sold 1,942 shares of ICU Medical stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $143.66, for a total value of $278,987.72. Following the completion of the transaction, the director now owns 6,760 shares of the company's stock, valued at approximately $971,141.60. This trade represents a 22.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 20,608 shares of company stock worth $2,843,617. Company insiders own 1.50% of the company's stock.

ICU Medical Trading Down 2.4%

Shares of NASDAQ ICUI traded down $3.38 during trading on Monday, reaching $138.00. The stock had a trading volume of 254,057 shares, compared to its average volume of 277,018. ICU Medical, Inc. has a fifty-two week low of $100.91 and a fifty-two week high of $196.26. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The business's 50-day moving average price is $140.78 and its 200-day moving average price is $153.61. The company has a market cap of $3.40 billion, a P/E ratio of -30.20 and a beta of 0.87.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share for the quarter, beating analysts' consensus estimates of $1.23 by $0.49. ICU Medical had a positive return on equity of 5.05% and a negative net margin of 4.74%. The business had revenue of $599.49 million during the quarter, compared to analysts' expectations of $574.15 million. During the same period in the previous year, the firm posted $0.96 earnings per share. The company's revenue was up 6.7% on a year-over-year basis. On average, equities research analysts predict that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.